Association between catechol O-methyltransferase [COMT] haplotypes and severity of hyperactivity symptoms in adults

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 3, 2009, Pages 403-410

  Halleland, H ^a   Lundervold, A J ^a,b   Halmoy A ^a   Haavik, J ^a,c   Johansson, S ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIFOB   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adult adhd; ASRS; COMT; Dopamine; Hyperactivity

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERKINESIS; IMPULSIVE BEHAVIOR; LINKAGE DISEQUILIBRIUM; MALE; NORWAY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 63449100481     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30831     Document Type: Article

References (46)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) 4th edition. Washington, DC: American Psychiatric Association.
2. Bellgrove MA, Domschke K, Hawi Z, Kirley A, Mullins C, Robertson IH, Gill M. 2005. The methionine allele of the COMT polymorphism impairs prefrontal cognition in children and adolescents with ADHD. Exp Brain Res 163(3):352-360.
3. Biederman J, Faraone SV. 2005. Attention-deficit hyperactivity disorder. Lancet 366(9481):237-248.
4. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer JP, et al. 2002. Neuro-cognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 52(7):701-707.
5. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL. 1989. Differential effects ofmethylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 2(4):255-263.
6. Caspi A, Langley K, Milne B, Moffitt TE, O'Donovan M, Owen MJ, Polo Tomas M, Poulton R, Rutter M, Taylor A, et al. 2008. A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 65(2):203-210.
7. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75(5):807-821.
8. Cheuk DK, Wong V. 2006. Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 36(5):651-659.
9. Congdon E, Canli T. 2005. The endophenotype of impulsivity: reaching consilience through behavioral, genetic, and neuroimaging approaches. Behav Cogn Neurosci Rev 4(4):262-281.
10. Craddock N, Owen MJ, O'Donovan MC. 2006. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes:Evidence and lessons. Mol Psychiatry 11(5):446-458.
11. Diamond AA. 2007. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cerebral Cortex 17(Suppl 1):70.
12. Dudbridge F. 2006. Unphased user guide. Cambridge, UK: MRC Biostatistics Unit.
13. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98(12):6917-6922.
14. Frank MJ, Moustafa AA, Haughey HM, Curran T, Hutchison KE. 2007. Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. Proc Natl Acad Sci USA 104(41):16311-16316.
15. Goldberg TE, Weinberger DR. 2004. Genes and the parsing of cognitive processes. Trends Cogn Sci 8(7):325-335.
16. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. 2003. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60(9):889-896.
17. Haavik J, Blau T, Thöny B. 2008. Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 29(7):891-902.
18. Handoko HY, Nyholt DR, Hayward NK, Nertney DA, Hannah DE, Windus
19. LC, McCormack CM, Smith HJ, Filippich C, James MR, et al. 2005. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 10(6):589-597.
20. Heiervang E, Stormark KM, Lundervold AJ, Heimann M, Goodman R, Posserud MB, Ullebo AK, Plessen KJ, Bjelland I, Lie SA, et al. 2007. Psychiatric disorders in Norwegian 8-to 10-year-olds: An epidemiological survey of prevalence, risk factors, and service use. J Am Acad Child Adolesc Psychiatry 46(4):438-447.
21. Johansson S, Halleland H, Halmoy A, Jacobsen KK, Landaas ET, Dram-sdahl M, Fasmer OB, Bergsholm P, Lundervold AJ, Gillberg C, et al. 2007. Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. Am J Med Genet Part B (in press).
22. Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z. 2008. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet Part B (in press).
23. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, et al. 2005. The World Health Organization Adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychol Med 35(2):245-256.
24. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics:Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6(3):243-250.
25. Levy F, McStephen M, Hay DA. 2001. the diagnostic genetics of ADHD symtoms and subtypes. In: Levy F, Hay DA, editors. Attention, genes, and ADHD. Philadelphia: Taylor &Francis. pp 35-37.
26. Lubke GH, Muthen B, Moilanen IK, McGough JJ, Loo SK, Swanson JM, Yang MH, Taanila A, Hurtig T, Jarvelin MR, et al. 2007. Subtypes versus severity differences in attention-deficit/hyperactivity disorder in the Northern Finnish Birth Cohort. J Am Acad Child Adolesc Psychiatry 46(12):1584-1593.
27. Mannisto PT, Kaakkola S. 1999. Catechol-O-methyltransferase (COMT):Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593-628.
28. McLoughlin G, Ronald A, Kuntsi J, Asherson P, Plomin R. 2007. Genetic support for the dual nature of attention deficit hyperactivity disorder:Substantial genetic overlap between the inattentive and hyperactive-impulsive components. J Abnorm Child Psychol 35(6):999-1008.
29. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, Mattay VS, Egan M, Weinberger DR. 2006. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 11(9):867-877, 797.
30. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. 2006. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314(5807):1930-1933.
31. Palmatier MA, Kang AM, Kidd KK. 1999. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 46(4):557-567.
32. Purcell S, Daly MJ, Sham PC. 2007a. WHAP: Haplotype-based association analysis. Bioinformatics 23(2):255-256.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. 2007b. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559-575.
34. Rapport MD, DuPaul GJ, Stoner G, Birmingham BK, Masse G. 1985.
35. Attention deficit disorder with hyperactivity: Differential effects of methylphenidate on impulsivity. Pediatrics 76(6):938-943.
36. Retz W, Rosler M, Kissling C, Wiemann S, Hunnerkopf R, Coogan A, Thome J, Freitag C. 2008. Norepinephrine transporter and catecholamine-O- methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm 115(2):323-329.
37. Reuter M, Kirsch P, Hennig J. 2006. Inferring candidate genes for attention deficit hyperactivity disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). J Neural Transm 113(7):929-938.
38. Sagvolden T, Johansen EB, Aase H, Russell VA. 2005. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28(3):397-419; discussion 419-468.
39. Sikstrom S, Soderlund G. 2007. Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol Rev 114(4):1047-1075.
40. Solanto MV. 2002. Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research. Behav Brain Res 130(1-2):65-71.
41. Stevenson J, Asherson P, Hay D, Levy F, Swanson J, Thapar A, Willcutt E. 2005. Characterizing the ADHD phenotype for genetic studies. Dev Sci 8(2):115-121.
42. Todd RD, Rasmussen ER, Neuman RJ, Reich W, Hudziak JJ, Bucholz KK, Madden PA, Heath A. 2001. Familiality and heritability of subtypes of attention deficit hyperactivity disorder in a population sample of adolescent female twins. Am J Psychiatry 158(11):1891-1898.
43. van der Meere J, Shalev R, Borger N, Gross-Tsur V. 1995. Sustained attention, activation and MPH in ADHD: a research note. J Child Psychol Psychiatry 36(4):697-703.
44. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. 1998. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155(10):1325-1331.
45. Volkow ND, Wang G, Fowler JS, Logan J, GerasimovM, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D. 2001. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21(2):RC121.
46. Zentall SS, Zentall TR. 1983. Optimal stimulation: A model ofdisordered activity and performance in normal and deviant children. Psychol Bull 94(3):446-471.